CareRx Corporation
TSX:CRRX.TOMedical - Care Facilities
+$0.02 today
- Market cap
- $203.06M
- Beta
- 0.62
- P/E (TTM)
- 7.4
- EPS (TTM)
- $0.43
- Dividend yield
- 1.88%
Volume 0.01M
Average 0.04M
CRRX.TO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
CareRx CorporationTSX: CRRX.TO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA grows, but more slowly than its trailing trend
Q1 FY2026 EBITDA of CA$7.96M rose 17.7% year over year, behind the +25.2% change in trailing-twelve-month EBITDA. Sequentially, it rose 5.6% from the prior quarter.
Context
- EBITDA amounted to 8.2% of revenue in FY2025, up 1.6 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of CA$31.66M (+4.8%) for the fiscal year ending Dec 2026, a slowdown from the +26.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- CA$7.96M+5.6% QoQ
- Last fiscal yearDec 2025
- CA$30.22M+26.4% YoY
- LTMMar 2026
- CA$30.12M+25.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +17.7% | +12.1% | -5.6 pp |
| 1 year | +26.4% | +4.8% | -21.6 pp |
| 3-year CAGR | — | +8.9% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
CAD · from the income statement
- Latest · FY2025
- 30.22M CAD
- Year-over-year change
- +26.4%
- 4-year CAGR
- +35.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.22M | +26.4% |
| FY2024 | 2024-12-31 | 23.9M | -3.0% |
| FY2023 | 2023-12-31 | 24.65M | +4141.1% |
| FY2022 | 2022-12-31 | (610K) | -106.8% |
| FY2021 | 2021-12-31 | 9.01M | — |
EBITDA vs competitors
How CRRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +25.2% is the 3rd highest of 6, against a peer median of +21.8%.
- EBITDA amounts to 8.0% of revenue for CRRX.TO, versus a peer median of 31.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $75.52M USD | -3.6% | +5.1% | 24.7% | |
| LTM Mar 2026 | CA$49.15M CAD | +45.8% | — | 31.0% | |
| LTM Mar 2026 | CA$30.12M CAD | +25.2% | — | 8.0% | |
| LTM Mar 2026 | $17.79M USD | +21.8% | +0.0% | 31.9% | |
| LTM Apr 2026 | -CA$3.08M CAD | +67.7% | — | — | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | -$36.45M USD | -1.4% | — | 194.3% |
| Peer median (excluding CRRX.TO) | — | +21.8% | +2.6% | 31.5% | |
Competitors are the stored peer set for CRRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 262.63M | 381.73M | 370.75M | 366.71M | 370.24M |
| Cost of Revenue | 187.35M | 271.79M | 286.02M | 258.65M | 277.61M |
| Gross Profit | 75.28M | 109.93M | 84.72M | 108.06M | 92.63M |
| Gross Margin | 28.7% | 28.8% | 22.9% | 29.5% | 25.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 70.52M | 102.55M | 77.5M | 32.75M | 34.23M |
| Operating Expenses | 70.47M | 82.24M | 100.03M | 103.54M | 80.75M |
| Depreciation & Amortization | 15.39M | 20.07M | 19.98M | 19.19M | 18.33M |
| EBITDA | 9.01M | (610K) | 24.65M | 23.9M | 30.22M |
| EBITDA Margin | 3.4% | -0.2% | 6.6% | 6.5% | 8.2% |
| Operating Income | (3.31M) | (21.94M) | 4.67M | 4.53M | 11.88M |
| Operating Margin | -1.3% | -5.7% | 1.3% | 1.2% | 3.2% |
| Interest Income | 58K | 278K | 1.26M | 63K | 161K |
| Interest Expense | 17.35M | 15.22M | 14.27M | 9.18M | 6.84M |
| Other Income / Expenses | (20.43M) | (13.95M) | (14.27M) | (8.99M) | (8.53M) |
| Income Before Tax | (23.74M) | (35.9M) | (9.6M) | (4.47M) | 3.35M |
| Pre-Tax Margin | -9.0% | -9.4% | -2.6% | -1.2% | 0.9% |
| Income Tax Expense | (1.01M) | (1.54M) | (4.19M) | 32K | (22.77M) |
| Net Income | (22.73M) | (34.35M) | (5.41M) | (4.5M) | 26.13M |
| Net Margin | -8.7% | -9.0% | -1.5% | -1.2% | 7.1% |
| EPS (Basic) | (0.65) | (0.72) | (0.09) | (0.07) | 0.42 |
| EPS (Diluted) | (0.65) | (0.72) | (0.09) | (0.07) | 0.41 |
| Weighted Avg Shares | 34.86M | 47.6M | 57.35M | 60.25M | 62.73M |
| Weighted Avg Shares (Diluted) | 34.86M | 47.6M | 57.35M | 60.25M | 64.49M |
CareRx Corporation
TSX:CRRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.